Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junji Furuse

Showing results (71-80 of 348) with videos related to

Pageof 35
Sort By:
Japanese Journal of Clinical Oncology|March 31, 2016
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)Junki Mizusawa, Chigusa Morizane, Takuji Okusaka, et al.
Japanese Journal of Clinical Oncology|November 22, 2022
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trialJunji Furuse, Makoto Ueno, Masafumi Ikeda, et al.
Endoscopy|March 8, 2024
Endoscopic ultrasound-guided gallbladder drainage using a forward-viewing echoendoscope after Billroth II gastrectomyYuichiro Tozuka, Kazuya Sugimori, Haruo Miwa, et al.
Trials|June 13, 2026
6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancreatic cancer in Japan (STARDOM, JON-2402P): study protocol for a multicenter randomized controlled trialDaiki Yamashige, Susumu Hijioka, Ichiro Yasuda, et al.
Cancer Chemotherapy and Pharmacology|December 31, 2014
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survivalAkiyoshi Kasuga, Naohiro Okano, Daisuke Naruge, et al.
Investigational New Drugs|October 19, 2023
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese expertsYoshitaka Honma, Masafumi Ikeda, Susumu Hijioka, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2008
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II studyJunji Furuse, Takuji Okusaka, Narikazu Boku, et al.
Surgery Today|March 12, 2018
APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomasYohei Kojima, Kouki Ohtsuka, Hiroaki Ohnishi, et al.
Critical Reviews in Oncology/Hematology|November 25, 2010
Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancerJunji Furuse, Takuji Okusaka, John Bridgewater, et al.
Japanese Journal of Clinical Oncology|September 11, 2014
EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsisKoji Yamaguchi, Takuji Okusaka, Kyoko Shimizu, et al.
Pageof 35

Showing results (71-80 of 348) with videos related to

Sort By:
Pageof 35
Japanese Journal of Clinical Oncology|March 31, 2016
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)Junki Mizusawa, Chigusa Morizane, Takuji Okusaka, et al.
Japanese Journal of Clinical Oncology|November 22, 2022
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trialJunji Furuse, Makoto Ueno, Masafumi Ikeda, et al.
Endoscopy|March 8, 2024
Endoscopic ultrasound-guided gallbladder drainage using a forward-viewing echoendoscope after Billroth II gastrectomyYuichiro Tozuka, Kazuya Sugimori, Haruo Miwa, et al.
Trials|June 13, 2026
6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancreatic cancer in Japan (STARDOM, JON-2402P): study protocol for a multicenter randomized controlled trialDaiki Yamashige, Susumu Hijioka, Ichiro Yasuda, et al.
Cancer Chemotherapy and Pharmacology|December 31, 2014
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survivalAkiyoshi Kasuga, Naohiro Okano, Daisuke Naruge, et al.
Investigational New Drugs|October 19, 2023
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese expertsYoshitaka Honma, Masafumi Ikeda, Susumu Hijioka, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2008
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II studyJunji Furuse, Takuji Okusaka, Narikazu Boku, et al.
Surgery Today|March 12, 2018
APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomasYohei Kojima, Kouki Ohtsuka, Hiroaki Ohnishi, et al.
Critical Reviews in Oncology/Hematology|November 25, 2010
Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancerJunji Furuse, Takuji Okusaka, John Bridgewater, et al.
Japanese Journal of Clinical Oncology|September 11, 2014
EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsisKoji Yamaguchi, Takuji Okusaka, Kyoko Shimizu, et al.
Pageof 35